Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | US Overactive Bladder (Anticholinergics & Beta Adrenoreceptor Agonists) Market Report: (2021-2031)The fastest growing market is the U.S. owing to continuous advancement in β3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs.
By: Koncept Analytics The three main treatment approaches for the treatment of overactive bladder are behavioural therapy (Bladder Training & Pelvic Floor Exercises), prescription therapy (Oral Anticholinergics & β3 Adrenoreceptor Agonist) and procedural therapy (BOTOX & Neuromodulation) The fastest growing market is the U.S. owing to continuous advancement in β3 Adrenoreceptor Agonist drugs, increasing OAB population and growing research & development efforts by domestic pharmaceutical firms to launch novel drugs with innovative mechanism of actions drugs. Scope of the report: • The report provides a comprehensive analysis of the U.S. OAB market, segmented on the basis of drug class i.e. Anticholinergics and β3 Adrenoreceptor Agonist and drug type i.e. Vibegron and Mirabegron. • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth. • The competitive landscape of the market, along with the company profiles of leading players [Allergan Plc, Pfizer Inc., Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Medtronic Plc and Sumitomo Chemical Co., Ltd. (Urovant Sciences Ltd.)] are also presented in detail. For more Information: https://www.konceptanalytics.com/ Koncept Analytics Vikas Gupta (Business Development Manager) FFCS-36, Ansal Plaza Vaishali, Ghaziabad U.P - 201010 Tele: +91-120-4130959 Mobile: +91-9871694789 Mail ID – vikas@konceptanalytics.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|